tetano
Editor, Senior Moderator
J Cell Mol Med
. 2020 Dec 18.
doi: 10.1111/jcmm.16198. Online ahead of print.
Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease
Shuai Yuan[SUP] 1 2 [/SUP], Peng Chen[SUP] 1 2 [/SUP], Huaping Li[SUP] 1 2 [/SUP], Chen Chen[SUP] 1 2 [/SUP], Feng Wang[SUP] 1 2 [/SUP], Dao Wen Wang[SUP] 1 2 [/SUP]
Affiliations
Abstract
To determine whether pre-hospitalization use of aspirin is associated with all-cause mortality in coronavirus disease 2019 (COVID-19) patients with coronary artery disease (CAD). We recruited 183 adult patients with CAD diagnosed with COVID-19, including 52 taking low-dose aspirin (mean [SD] age, 69.7 [1.1] years; 59.6% men) and 131 without using aspirin (mean [SD] age, 71.8 [0.9] years; 51.9% men), who were admitted in the Tongji hospital in Wuhan, China from January 10, 2020 to March 30, 2020. There was no difference on in-hospital mortality between aspirin group and non-aspirin group (21.2% vs. 22.1%, P = .885). Similarly, for critically severe COVID-19 patients, the mortality in aspirin group was close to that in non-aspirin group (44% vs. 45.9%, P = .872). Moreover, the percentage of patients with CAD taking low-dose aspirin did not differ between those survivors and non-survivors (28.7% vs. 27.5%, P = .885). Meanwhile, the usage of aspirin was not correlated with all-cause mortality in multivariate analysis (OR = 0.944, 95% CI: 0.411-2.172, P = .893). Collectively, our study suggested that the pre-hospitalization use of low-dose aspirin was not associated with the clinical outcome of patients with CAD hospitalized with COVID-19 infections.
Keywords: COVID-19; SARS-CoV-2; aspirin; coronary artery disease.
. 2020 Dec 18.
doi: 10.1111/jcmm.16198. Online ahead of print.
Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease
Shuai Yuan[SUP] 1 2 [/SUP], Peng Chen[SUP] 1 2 [/SUP], Huaping Li[SUP] 1 2 [/SUP], Chen Chen[SUP] 1 2 [/SUP], Feng Wang[SUP] 1 2 [/SUP], Dao Wen Wang[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33336936
- DOI: 10.1111/jcmm.16198
Abstract
To determine whether pre-hospitalization use of aspirin is associated with all-cause mortality in coronavirus disease 2019 (COVID-19) patients with coronary artery disease (CAD). We recruited 183 adult patients with CAD diagnosed with COVID-19, including 52 taking low-dose aspirin (mean [SD] age, 69.7 [1.1] years; 59.6% men) and 131 without using aspirin (mean [SD] age, 71.8 [0.9] years; 51.9% men), who were admitted in the Tongji hospital in Wuhan, China from January 10, 2020 to March 30, 2020. There was no difference on in-hospital mortality between aspirin group and non-aspirin group (21.2% vs. 22.1%, P = .885). Similarly, for critically severe COVID-19 patients, the mortality in aspirin group was close to that in non-aspirin group (44% vs. 45.9%, P = .872). Moreover, the percentage of patients with CAD taking low-dose aspirin did not differ between those survivors and non-survivors (28.7% vs. 27.5%, P = .885). Meanwhile, the usage of aspirin was not correlated with all-cause mortality in multivariate analysis (OR = 0.944, 95% CI: 0.411-2.172, P = .893). Collectively, our study suggested that the pre-hospitalization use of low-dose aspirin was not associated with the clinical outcome of patients with CAD hospitalized with COVID-19 infections.
Keywords: COVID-19; SARS-CoV-2; aspirin; coronary artery disease.